Jadenu 90 mg is a Product of the Generic Deferasirox

What Is Jadenu 90 mg Indications and Uses?

Jadenu 90 mg (Deferasirox) is indicated for the treatment of chronic iron overload due to repeated blood transfusions in adult and pediatric patients aged 2 years and over with thalassaemia, sickle cell disease and myelodysplastic syndrome. Also indicated for treating chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Pharmacology (Source, Chemical and Physical Composition) Of Jadenu 90 mg

Jadenu 90 mg (Deferasirox) is an orally active chelator that is highly selective for iron, It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Deferasirox promotes excretion of iron, primarily in the faeces. Deferasirox has low affinity for zinc and copper, and does not cause constant low serum levels of these metals. In an iron balance metabolic study in iron overloaded adult thalassaemia patients, Deferasirox at daily doses of 10, 20 and 40 mg/kg induced the mean net excretion of 0.119, 0.329, and 0,445 mg Fe/kg body weight/day, respectively.

Drug Interactions of Jadenu 90 mg

Should not be taken with aluminium-containing antacids, Caution to be taken when combined with drugs metabolized through CYP3A4 (e.g. cyclosporine, simvastatin, hormonal contraceptive, midazolam). Dose increase should be considered when concomitantly used with rifampicin, phenytoin, phenobarbital, ritonavir etc. Interaction with other CYP2C8 substrates like paclitaxel cannot be excluded. Caution to be taken when combined with drugs with ulcerogenic potential (e.g. NSAIDS, corticosteroids, oral bisphosphonates) or with anticoagulants.

Side Effects of Jadenu 90 mg

Cytopenias may occur diarrhea, constipation, vomiting, nausea, abdominal pain, abdominal distension, dyspepsia upper gastrointestinal ulceration and hemorrhage have been reported. Headache, dizziness and main CNS involvement. Elevation of hepatic transaminases may occur. Cases of Stevens-Johnson syndrome (SJS) and skin rash have been rarely reported. Auditory and ocular disturbances may occur.

Precautions And Warnings for Jadenu 90 mg

Fatal and non-fatal gastrointestinal bleeding, ulceration, and irritation may occur during Jadenu 90 mg (Deferasirox) treatment , Use caution in patients who are taking Jadenu in combination with drugs that have known ulcerogenic or hemorrhagic potential, such as NSAIDs, corticosteroids, oral bisphosphonates, and anticoagulants. Cytopenias, including agranulocytosis, neutropenia and thrombocytopenia have been reported. Monitor blood counts during Jadenu therapy. Serious hypersensitivity reactions have been reported, If reactions are severe, discontinue Jadenu and institute appropriate medical intervention.

Use During Pregnancy and Lactation

Pregnancy Category C. There are no adequate and well-controlled studies with Jadenu 90 mg (Deferasirox) in pregnant women. Administration of Deferasirox to animals during pregnancy and lactation resulted in decreased offspring viability and an increase in renal anomalies in male offspring at exposures that were less than the recommended human exposure. Deferasirox should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Deferasirox is excreted in human milk.

Therapeutic Class

Antidote preparations

Storage Conditions of It

Store in a dry place below 25°C, and protect from light. Keep out of the reach of children. Pack Image: Jadenu 90 mg Tablet Thanks for using MedEx! How would you rate your experience so far?